Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: A study from the Western Denmark Heart Registry

1Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: We evaluated the effectiveness and safety of a zotarolimus-eluting (ZES) versus a sirolimus-eluting (SES) coronary stent in a large cohort of patients treated with one of these stents in Western Denmark.Methods: A total of 6,122 patients treated with ZES (n=2,282) or SES (n=3,840) were followed for up to 27 months. We ascertained clinical outcomes based on national medical databases.Results: Incidence of target lesion revascularization (no. per 100 person-years) was 5.3 in the ZES group compared to 1.9 in the SES group (adjusted hazard ratio (HR)=2.19, 95% confidence intervals (CI): 1.39-3.47; p=0.001). All-cause mortality was also higher in the ZES group (ZES: 6.3; SES: 3.3; adjusted HR=1.34, 95% CI: 1.05-1.72; p=0.02), while stent thrombosis (ZES: 1.2; SES: 0.5; adjusted HR=1.98, 95% CI: 0.75-5.23; p=0.14) did not differ significantly.Conclusions: In agreement with previously published randomised data, this observational study indicated that the ZES was associated with an increased risk of death and TLR in a large cohort of consecutive patients. © 2012 Maeng et al.; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Maeng, M., Jensen, L. O., Kaltoft, A., Tilsted, H. H., Christiansen, E. H., Thayssen, P., … Thuesen, L. (2012). Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: A study from the Western Denmark Heart Registry. BMC Cardiovascular Disorders, 12. https://doi.org/10.1186/1471-2261-12-84

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free